This handout is for glucocorticoid-induced hypertensive crisis (severe htn driven by high-dose prednisone >20 mg/d, methylprednisolone, or hydrocortisone via mineralocorticoid receptor activation, na+ retention, raas upregulation, and vascular sensitization — fluorinated dexamethasone less implicated). Your care team identified this based on: high-dose glucocorticoid therapy (prednisone >20 mg/d, methylprednisolone iv, hydrocortisone replacement-plus, or stress-dose iv) with new sbp ≥180 / dbp ≥120 — chronic high-dose use commonly precipitates within 2-6 weeks (fardet j hypertens 2011).
Other reasons your team may use this plan: recent iv pulse methylprednisolone (500-1000 mg/d for sle flare, transplant rejection, ms flare, vasculitis) → acute bp spike within hours to days — high mineralocorticoid effect at pulse doses; high-dose glucocorticoid + concurrent nsaid (additive na+ retention + raas) → severe htn crisis with hypok + edema; classic outpatient presentation; moon face + buffalo hump + central obesity + striae + new severe htn — chronic high-dose steroid cushingoid presentation with crisis.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nicardipine | 5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h | IV | continuous infusion | AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded steroid patients |
| spironolactone | 25-100 mg PO daily (load 100 mg PO once if severe; maintenance 25-50 mg PO daily); titrate per K + BP | PO | daily | Funder NEJM 2003 PMID 14507948 + Williams JAMA 2018 PMID 30575491 — MR antagonist directly blocks the offending mineralocorticoid effect of high-dose glucocorticoid at the receptor level; pathophysiologically targeted therapy + corrects hypoK + addresses Na+ retention |
| eplerenone | 25-50 mg PO BID (max 100 mg/d) | PO | BID | Selective MR antagonist without anti-androgen effects (no gynecomastia); slightly less potent than spironolactone but better tolerated long-term |
| labetalol | 10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min | IV | PRN bolus or continuous | Mixed α/β safe in steroid-induced HTN (no unopposed-alpha concern); standard HTN-emergency adjunct per AHA 2025 |
| furosemide | 20-40 mg IV (cautious — combine with K replacement + spironolactone protection) | IV | q6-12h PRN | Adjunct for volume overload; CAUTION — worsens hypoK alone; use only with concurrent K replacement + spironolactone to protect K |
| potassium chloride | KCl 40 mEq PO TID OR 10-20 mEq IV/h (max 20 mEq/h peripheral, 40 mEq/h central) | PO + IV | as needed to target K 4-5 | Steroid-induced MR activation → K wasting → hypoK common; aggressive replacement essential before BP control fully effective |
| magnesium sulfate | 2-4 g IV (1-2 g/h infusion if severe) | IV | as needed to target Mg 2.0-2.5 | HypoMg coexists with hypoK; correct Mg first or K replacement ineffective; arrhythmia prevention |
| dexamethasone | 0.75 mg = 5 mg prednisone equivalent (convert at equipotent dose) | PO/IV | per indication | Fluorinated steroid has MINIMAL mineralocorticoid receptor activity vs prednisone/methylprednisolone/hydrocortisone; switch when clinically possible to reduce MR-driven HTN + hypoK while maintaining glucocorticoid effect |
| hydrocortisone (stress-dose for adrenal insufficiency rescue) | 100 mg IV bolus then 50-100 mg IV q6-8h × 24-48 h then slow taper | IV | q6-8h then taper | Iatrogenic adrenal insufficiency from over-rapid taper after >2 weeks chronic use; stress-dose protocol per Endocrine Society 2016 |
| STEROID-SPARING TRANSITION (DMARDs, biologics, calcineurin inhibitors) | MTX 7.5-25 mg/wk + folic acid; OR hydroxychloroquine 200-400 mg/d; OR azathioprine 1-2.5 mg/kg/d; OR cyclosporine 2-5 mg/kg/d; OR biologics (rituximab, tocilizumab, TNFi per disease) | PO + IV | per regimen | ACR 2017 PMID 28585410 — long-term goal is lowest effective steroid dose with steroid-sparing immunosuppression; specialty-led (rheum, ID, onc, transplant) |
| PROPHYLACTIC SPIRONOLACTONE during high-dose courses | 25-50 mg PO daily during prednisone >20 mg/d courses, especially planned >2 weeks | PO | daily | AACE 2024 + emerging consensus — prophylactic MR-blockade prevents steroid-induced HTN + hypoK in high-dose courses; consider routinely with prednisone >20 mg/d × ≥2 weeks |
| AVOID concurrent NSAIDs during steroid therapy | AVOID | N/A | N/A | NSAID + steroid synergistic Na+ retention + RAAS upregulation + GI bleed risk; substitute acetaminophen + topical NSAID + adjuvants for pain control |
| STEROID TAPER plan (gradual over 4-12 weeks if chronic >2 weeks use) | Reduce by 5-10 mg/week if prednisone >40 mg, 2.5-5 mg/week if 20-40 mg, 1-2.5 mg/week if <20 mg; switch to alternate-day dosing in last phase | PO | graduated reduction | Endocrine Society 2016 — gradual taper avoids adrenal insufficiency from HPA axis suppression; Synacthen test if uncertain about recovery |
| BONE PROTECTION: bisphosphonate + Ca + vit D + DEXA | Alendronate 70 mg PO weekly OR zoledronate 5 mg IV annually + Ca 1200 mg/d + vit D 800-2000 IU/d; DEXA at baseline + q1-2 years | PO + IV | weekly/annually | ACR 2017 PMID 28585410 — glucocorticoid-induced osteoporosis prevention in chronic users >5 mg prednisone for ≥3 months |
Plan: Glucocorticoid-induced HTN crisis — IV nicardipine first-line + SPIRONOLACTONE 25-100 mg PO (block offending MR effect) + aggressive K/Mg replacement + REDUCE/CONVERT steroid (switch to dexamethasone, lowest MR activity) + steroid-sparing transition (DMARDs/biologics) + prophylactic MR-blockade during chronic high-dose courses
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
STEROID MINIMIZATION: confirmed plan to taper to lowest effective dose (or off) over 4-12 weeks per indication + disease control; STEROID-SPARING TRANSITION: rheum/ID/onc-led DMARD/biologic/calcineurin-inhibitor introduction with overlap (MTX, hydroxychloroquine, azathioprine, cyclosporine, biologics like rituximab/tocilizumab/TNFi); PROPHYLACTIC SPIRONOLACTONE 25-50 mg PO daily during ongoing high-dose courses; BP MONITORING: weekly home BP during steroid taper, monthly during chronic low-dose maintenance; K MONITORING: q1-2 weeks during steroid + spironolactone titration; STEROID-RELATED COMPLICATION SURVEILLANCE: bone density (DEXA + bisphosphonate prophylaxis if >5 mg prednisone equivalent for ≥3 months — ACR 2017 PMID 28585410), HbA1c (steroid-DM screening q3 months), lipid panel, ophthalmology (cataracts, glaucoma), PCP prophylaxis if >20 mg prednisone for ≥1 month (TMP-SMX or atovaquone), VZV reactivation surveillance, vaccination optimization (avoid live vaccines on >20 mg prednisone); ADRENAL AXIS RECOVERY: stress-dose protocol issued + medical-alert bracelet for chronic steroid users; PSYCHIATRIC follow-up if steroid psychosis history; PCP + endocrinology + relevant specialty (rheum/ID/onc) follow-up within 1-2 weeks
Guideline: 2025 ACC/AHA HTN Guideline (Whelton) + ACR 2017 GC use in rheumatic disease (Buckley PMID 28585410) + AACE 2024 glucocorticoid-induced metabolic complications consensus + Endocrine Society 2016 adrenal insufficiency